Novo Nordisk has announced a major strategic expansion of its metabolic disease portfolio, entering into a significant licensing agreement with Chinese pharmaceutical leader Hengrui Pharma for HRS-1596, a promising next-generation weight management and diabetes candidate.
The deal grants Novo Nordisk exclusive global rights to develop, manufacture, and commercialize HRS-1596, a phase 1-ready dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR). The agreement excludes mainland China, Hong Kong, Macao, and Taiwan, where Hengrui will retain control.
Under the financial terms of the agreement, the deal is valued at up to $2.6 billion, contingent upon the successful completion of development, regulatory, and commercial milestones. The transaction includes an immediate $300 million upfront payment to Hengrui Pharma, which will also be eligible for tiered royalties based on future net sales within the licensed territories.
HRS-1596 represents a significant technological leap in metabolic care. By functioning as a dual agonist, the drug is designed to suppress appetite while simultaneously stimulating insulin secretion and enhancing insulin sensitivity. Crucially, the molecule has been engineered with the potential for once-weekly oral administration. If successful, this would offer a distinct advantage over current injectable-heavy treatment regimens, potentially setting a new standard for patient convenience and adherence in the treatment of obesity and type 2 diabetes.
“Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center,” said Martin Holst Lange, executive vice president of Research & Development and Chief Scientific Officer at Novo Nordisk. “We are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”
Frank Jiang, executive vice president and Chief Strategy Officer of Hengrui Pharma, echoed this sentiment, stating, “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”
The partnership marks a continuation of Hengrui Pharma’s aggressive international expansion strategy. In recent months, the Chinese company has become a primary target for global pharmaceutical giants looking to bolster their pipelines. Earlier this year, Hengrui partnered with Bristol Myers Squibb (BMS) to advance a portfolio of 13 early-stage oncology, hematology, and immunology programs. The company also secured high-profile development pacts with GSK and Merck throughout 2025, cementing its reputation as a powerhouse of drug discovery.
The license agreement between Novo Nordisk and Hengrui is subject to customary closing conditions, including clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act. Both companies expect the transaction to formally close in the fourth quarter of 2026, as Hengrui moves forward with initial phase 1 clinical trials for the drug in China.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
